Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease by Hope, Holly F et al.
 
 
University of Birmingham
Systematic review of the predictors of statin
adherence for the primary prevention of
cardiovascular disease
Hope, Holly F; Binkley, George M; Fenton, Sally; Kitas, George D; Verstappen, Suzanne M
M; Symmons, Deborah P M
DOI:
10.1371/journal.pone.0201196
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Hope, HF, Binkley, GM, Fenton, S, Kitas, GD, Verstappen, SMM & Symmons, DPM 2019, 'Systematic review of
the predictors of statin adherence for the primary prevention of cardiovascular disease', PLoS ONE, vol. 14, no.
1, e0201196. https://doi.org/10.1371/journal.pone.0201196
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Hope HF, Binkley GM, Fenton S, Kitas GD, Verstappen SMM, Symmons DPM (2019) Systematic review of the predictors of statin
adherence for the primary prevention of cardiovascular disease. PLoS ONE 14(1): e0201196. https://doi.org/10.1371/journal.pone.0201196
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
RESEARCH ARTICLE
Systematic review of the predictors of statin
adherence for the primary prevention of
cardiovascular disease
Holly F. HopeID1☯¤*, George M. Binkley1☯, Sally Fenton2‡, George D. KitasID2,3‡, Suzanne
M. M. Verstappen1,4‡, Deborah P. M. Symmons1‡
1 Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology,
Medicine and Health, The University of Manchester, Manchester. England, 2 School of Sport, Exercise and
Rehabilitation Sciences, University of Birmingham, Edgbaston, Birmingham, England, 3 Rheumatology
Department, Russells Hall Hospital, Dudley Group NHS Foundation Trust, Dudley, England, 4 NIHR
Manchester Biomedical Research Centre, Central Manchester University Hospitals NHS Foundation Trust,
Manchester, England
☯ These authors contributed equally to this work.
¤ Current Address: Centre for Women’s Mental Health, Division of Psychology and Mental Health, School of
Health Sciences, University of Manchester, Manchester England
‡ These authors also contributed equally to this work.
* holly.hope@manchester.ac.uk
Abstract
Introduction
Previous research has shown that statin adherence for the primary prevention of CVD is
lower compared to secondary prevention populations. Therefore the aim of this systematic
review was to review predictors of statin adherence for the primary prevention of CVD.
Methods
A systematic search of papers published between Jan 1984 and May 2017 was conducted
in PubMed, PsycINFO, EMbase and CINAHL databases. A study was eligible for inclusion
if; 1) it was a study of the general population or of patients with familial hypercholesterol-
emia, hypertension, diabetes or arthritis; 2) statins were prescribed; 3) adherence was
defined and measured as the extent to which patients followed their statin regimen during
the period of prescription, and 4) it was an original trial or observational study (excluding
case reports). A study was subsequently excluded if 1) results were not presented sepa-
rately for primary prevention; 2) it was a trial of an intervention (for example patient educa-
tion). Papers were reviewed by two researchers and consensus agreed with a third. A
quality assessment (QA) tool was used to formally assess each included article. To evaluate
the effect of predictors, data were quantitatively and qualitatively synthesised.
Results
In total 19 studies met the inclusion criteria and nine were evaluated as high quality using
the QA tool. The proportion of patients classed as “adherent” ranged from 17.8% to 79.2%.
Potential predictors of statin adherence included traditional risk factors for CVD such as
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age, being male, diabetes and hypertension. Income associated with adherence more
strongly in men than women, and highly educated men were more likely and highly educated
women less likely to be adherent. Alcohol misuse and high BMI associated with non-adher-
ence. There was no association between polypharmacy and statin adherence. The evi-
dence base for the effect of other lifestyle factors and health beliefs on statin adherence was
limited.
Conclusion
Current evidence suggests that patients with more traditional risk factors for CVD are more
likely to be adherent to statins. The implications for future research are discussed.
Introduction
HMG-CoA (3-hydroxy-3-methyl-glutaryl-coenzyme) reductase is the rate-controlling enzyme
of the mevalonate pathway, the metabolic pathway that produces low density lipoprotein cho-
lesterol (LDLc). HMG-CoA reductase inhibitors (statins) reduce the level of LDL-C and other
isoprenoids (lipids) and thereby lower the risk of atherosclerosis and cardiovascular disease
(CVD) [1]. Statins also have multiple other (so called pleiotropic) effects which may contribute
to the reduction of CVD risk including effects that stabilise atherosclerotic plaques, support
endothelial function and reduce inflammation of the vasculature [2]
Whilst statins are used for the primary and secondary prevention of CVD the risk of death
is lower for the primary prevention population, therefore it is important to evaluate the benefit
of statins in this setting separately. Data from a prior meta-analysis of eleven randomised con-
trolled trials (RCTs) indicated there was no association between statin use and all-cause mor-
tality (RR 0.91, 95% CI 0.81–1.01) [3]. More recently, Taylor et al. conducted a Cochrane
review of 18 RCTs and 19 observational studies and reported compared to placebo, statins
reduced lipid levels and also the risk of experiencing a fatal or non-fatal cardiovascular event
(CVE) by a quarter (RR 0.73, 95% CI 0.67–0.80), the equivalent number needed to treat
(NNT) for five years was 56 (95% CI 46–75) [4]. They also analyzed the incidence of adverse
events, including cancer, myalgia and rhabdomyolysis, arthritis, and increased liver enzyme,
and found no evidence of increased risk for statin users compared to placebo or control partic-
ipants, except in one trial in which there was an increased risk of type II diabetes [4]. The
authors postulated there may be a risk of stroke, but there was no data to investigate this, and
the authors recognized that not all trials in their review investigated side effects. Thus, there is
evidence for cardiovascular but not wider benefits from statins use in the primary prevention
setting.
Current UK clinical guidelines recommend that a person with at least a one in ten risk of
experiencing a fatal or non-fatal CVE in the next ten years should be offered atorvastatin at
20mg daily or an equivalent dose of another licensed statin for its primary prevention [1]. The
risk of primary CVD is calculated using a cardiovascular risk calculator. The QRISK3 calcula-
tor is most commonly used in the UK [5], the Framingham Risk Score (FRS) in the US [6],
and the Systematic Coronary Risk Evaluation (SCORE) in Europe [7]. All of these calculators
include the following components to calculate the risk of CVD; age, gender, smoking status,
systolic blood pressure, the level of LDL-C and presence of co-morbid diabetes and hyperten-
sion, and some contain additional factors [8].
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Once a clinician has prescribed statins, the extent to which these therapies will be effective
is directly associated with the patient’s adherence to their treatment regimen [9]. A recent
meta-analysis of rates of adherence in patient populations over 65 years of age revealed adher-
ence to statins indicated for the primary prevention of CVD was suboptimal. At one year, only
47.9% were adherent and 24% had discontinued their therapy [10]. In 2013, a meta-analysis of
44 studies which investigated the relationship between statin adherence and mortality in pri-
mary and secondary populations found that 60% of 1,978,919 subjects were adherent. Adher-
ence in this case was measured using pharmacy records and defined by calculating the ratio of
the number of days that the patient had medication divided by the total number of days the
patient was ‘observed’ (medication possession ratio (MPR)). An MPR� 80% is classified as
adherent. This level of adherence was associated with a reduced risk of all-cause mortality (RR
0.55, 95%CI 0.46–0.67) and CVD mortality (RR 0.85, 95%CI 0.81–0.89) which is equivalent to
one CVD outcome per 10,000 individuals. The absolute risk is small, however it was calculated
using the standardised death rate for people under the age of 65 and thus will be higher in
older age-groups with higher baseline risks [11]. The greater reduction in all-cause mortality is
supportive of a ‘healthy adherer’ effect, where adherence to statins is an indicator of other
health promoting behaviours [12]. More recently, observational studies using registry data
have reported a dose dependent relationship between increasing levels of adherence and
reductions in cholesterol levels and CVD [13–15]. This relationship is apparent even at the
highest levels of adherence; patients with 90–100% adherence (measured using MPR) were sig-
nificantly more likely to have a reduction in LDL, high density lipoproteins and total choles-
terol levels by at least 25% compared to those with 80–89% adherence [14]. In addition to the
demonstrable health benefits associated with optimal statin use there are also economic bene-
fits to high levels of adherence, and these cost benefits increase as the baseline risk of a primary
CVE increases [16,17].
These studies highlight the need to optimise statin use for people at risk of a CVE. In order
to improve adherence to statins in the primary prevention population, the predictors of and
reasons for statin non-adherence need to be understood. Non-adherence can be intentional or
unintentional. Intentional non-adherence refers to a person’s decision to take drug-holidays
or stop the medication, and unintentional non-adherence includes forgetting or running out
of medication. The extent to which non-adherence occurs is related to the cognitive, emotional
and financial resources of the patient, and their healthcare context [18]. Systematic reviews of
other long-term medications have identified psychological factors such as mood, treatment
beliefs and coping strategies as important predictors of adherence. Qualitative research with a
primary prevention cohort found that reasons for intentional statin non-adherence or discon-
tinuation included perceived side effects and the inflexibility of the healthcare provider to
switch statins [19].
Previous systematic reviews have focussed on statin non-adherence rather than adherence
and identified the following risk factors for non-adherence; high cost, low income, absence of
co-morbidities, infrequent lipid monitoring, high intensity dosing and being an incident user
versus existing user of statins [20–23]. Importantly, these reviews included both primary and
secondary prevention population studies in their analyses and the prescription of statins for
the primary prevention of CVE was shown to have the largest pooled effect size on the risk of
non-adherence. A recent study demonstrated that patients identified as statin non-adherent
prior to their first CVE were less likely to be non-adherent post hospitalisation, which illus-
trates the difference between primary and secondary prevention populations with respect to
adherence [24]. The evidence suggests thus far that the primary prevention population appears
to be at greater risk of non-adherence. Given the negative consequences of non-adherence in
this population with respect to increased risks of CVD, identifying the risks of statin non-
Systematic review of the predictors of statin adherence
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adherence specific to the primary prevention setting is merited. Lemstra et al. lamented the
lack of studies investigating the effect of psychological and lifestyle factors on adherence [20].
Factors such as depression, medication and illness beliefs have been shown to predict non-
adherence to other long-term medications [25]. A contemporary meta-analysis of interven-
tions to improve statin adherence found strategies such as patient education, counselling, sim-
plifying regimens, issuing reminders and even interventions classed as multi-faceted that
included a combination of the above strategies only achieved small positive effects upon adher-
ence (Hedges g<0.5) [26]. Clearly there is a need to investigate the reasons for and predictors
of adherence in more depth as this will allow for better targeted and tailored strategies to opti-
mise statin adherence for the primary prevention of heart disease.
Therefore the aim of this systematic review is to identify predictors of statin adherence for
the primary prevention of CVD.
Methods
Search strategy
EMbase, Medline, CINAHL (Cumulative Index to Nursing and Allied Health Literature) and
PsycInfo databases were searched from January 1984 (when the first trials of statins were pub-
lished) until May 2017 [27], using Patient Intervention Comparison Outcome (PICO) search
methodology to build the following strategy [28]: P)Primary prevention as the patient popula-
tion; I) one or more statins as an intervention; C) predictors of adherence as comparators and
O) adherence as a measured study outcome. The PICO comparison category would be identi-
fied at subsequent stages of the selection process. Synonyms for each PICO category were
defined and the databases searched to identify abstracts that included a synonym from each
category in the title, original title, abstract, subject heading, name of substance, or registry
word fields (S1 Table). The apriori review protocol is available upon request.
Study inclusion
Studies obtained from the systematic search were eligible for inclusion if: 1) People were
receiving treatment for the primary prevention of CVD or the results were given separately
for primary prevention; 2) a statin was prescribed; 3) adherence was defined as the extent to
which patients followed their statins regimen during the period of prescription, rather than
the length of time till statin discontinuation; 4) predictors of adherence were defined and mea-
sured and 5) the study was a piece of original research (including abstract, thesis or conference
proceedings). Titles and abstracts obtained from the search were independently evaluated by
two researchers HH, SF and, where there was a disagreement, adjudicated by a third reviewer
(DS). If the cohort was not defined as primary or secondary prevention cohort, for example
if registry or pharmacy refill datasets were used to create ‘incident statin user’ cohorts, the
reviewers assumed these analyses would include at least some incident statin use after a CV
event or diagnosis and therefore these studies were excluded from the review. If primary and
secondary prevention populations were jointly investigated, studies were only included if
results specific to the primary prevention sample were evident. If the number or proportion of
patients in adherent and non-adherent groups were presented these data were extracted and
odds ratios for adherence calculated. Trials were included if there were secondary analyses of
both arms of the study that investigated predictors of adherence.
If original research met the inclusion criteria but only existed as an abstract, thesis or
conference proceedings, and the effect of factors on adherence was available it was included.
Relevant reviews and opinion articles were retrieved in order to cross reference to ensure all
relevant articles were included.
Systematic review of the predictors of statin adherence
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Quality assessment
The quality of the included studies was formally assessed using the quality assessment tool
measure used in a previous published systematic review by Hope et al [25]. The quality assess-
ment consisted of sixteen items, adapted from the recommendations of Sanderson et al. which
state that observational studies should be evaluated on the use of appropriate methods to: 1)
select participants, 2) measure exposure and outcome variables, 3) control for confounding, 4)
reduce bias and 5) analyse data [29] (S2 Table). The authors judged papers that scored fourteen
or more as high quality (range (0–17)). Trials were judged using the same criteria, since the
data were analysed as if they were prospective cohort studies.
Evidence synthesis
Quantitative synthesis. Rates of non-adherence were inverted to calculate a rate of adher-
ence for each study. A predictor was selected for quantitative pooling if there were at least
three studies with a combined sample�1000 that investigated the same or similar predictor
using the same or similar analysis (binary versus continuous data). Where cohorts were strati-
fied by age, the effect size and the sample size of said strata were entered as separate effects into
the meta-analysis. Where studies had stratified their cohort and obtained separate estimates
for each cohort these were treated as separate cohort studies. Where studies had used the same
data source the study with the larger sample size was included in the meta-analysis unless the
effect was only investigated in the smaller study. These estimates were pooled using a fixed
effects meta-regression analysis that adjusted for the study sample size. The I2 statistic was
used to evaluate the proportion of variance across the studies attributable to study heterogene-
ity. Sensitivity analyses of adjusted and unadjusted effect sizes, period of follow-up (� 1 year, 1
year,> 1 year), region, gender distribution, age range, measure of adherence and % adherent
(< 50% versus� 50%) were conducted to identify possible sources of heterogeneity.
Qualitative synthesis. Predictor data that did not meet criteria for quantitative synthesis,
or data where the pooled estimate possessed high heterogeneity (I2>50%), were qualitatively
compared across studies and evaluated based on the definitions of strong, moderate, limited
and conflicting evidence of van Tulder and colleagues [30]. Strength of evidence for an associa-
tion was graded 1–5, where 5 meant there were multiple high quality studies, where high quality
meant the study scored�14 on the QA score and the specific analysis adjusted for potential
confounding, with a total sample size�1000. To score four there had to be a total sample size
�1000 from several studies including one high quality study. To score 3 there had to be evi-
dence from one high quality study, or several low quality studies with a total sample size�1000.
To score 2 the evidence was taken from several low quality studies or one high quality study
with a total sample<1000, and 1 was scored where there was only one low quality study with a
sample less than 1000. Where there were inconsistent findings with the same level of evidence
these were classed as ‘0’ to indicate conflicting evidence. The evidence could be conflicting in
relation to the presence of or direction of an effect (Table 1). All unique predictors were
included in the qualitative synthesis. Where studies utilised the same cohorts and duplicate
effects existed then the effect size from the higher quality study was included in the synthesis.
Results
The systematic search generated 2049 abstracts, a further 12 were included after snowballing
and after duplicates (n = 284) were removed. 1777 abstracts were screened. After screening
257 abstracts fulfilled the inclusion criteria and a full paper review was performed. Some
papers had to be excluded because the patient cohort was not clearly defined (n = 23) or the
primary and secondary prevention cohorts were analysed together (n = 118). Other papers
Systematic review of the predictors of statin adherence
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were excluded because variables were not compared across adherence levels (n = 34), or there
was insufficient data to include (n = 28), discontinuation or persistence were measured rather
than adherence (n = 23), or they were fixed dose combination (FDC) therapies (n = 11). A
total of 19 papers fulfilled all inclusion criteria (Fig 1).
Study characteristics
The review consists of three cross-sectional studies [31–33], eleven retrospective cohort stud-
ies [34–44], three prospective cohort studies [45–47] and two randomised controlled trials
(RCTs) [48, 49] (Total n = 19). Of the retrospective studies, one was stratified by gender [34],
one by age and gender [44] and one by length of follow-up [36]. The included RCTs contained
analyses which combined patients from treatment and comparator arms that investigated the
association between patient factors and adherence [48,49]. Nine studies were judged to have a
quality assessment score of fourteen or more and to have adequately controlled for potential
biases in their study design and planned data analyses [32,34–36,38,39,44,46,47]. Adherence
was not the primary outcome in six studies [37,39–43], only seven adjusted for the effect of
other variables upon adherence [31,34–36,38,44,46]. Ten studies used statin refill data
extracted from drug registries and calculated the proportion of days covered (PDC) or a MPR
[34–42,44–47]. Adherence was electronically monitored in one study and a composite measure
of adherence to the dose and schedule was calculated [49]. Five studies used self-report mea-
sures; some of which were validated [31,32,47]; the remainder used bespoke self-report mea-
sures [33,48]. Adherence was assessed over time periods as brief as one month [33] to five
years [37]. Most studies investigated predictors of being adherent, where being adherent was
defined as adherence�80%. Specific cut-offs on self-reported measures were used to define
being adherent or endorsement of the adherent behaviour (e.g. yes, I am adherent). In one
study no-one self-reported high adherence so a cut-off of moderate adherence was used [31].
One study did not include predictors but it did contain reasons for non-adherence so it
remained in the review [33]. Only one study investigated the predictors of adherence using a
continuous adherence outcome [49].
The proportion of patients included in the review defined as adherent ranged from 17.8%
to 79.2%, which indicates that overall adherence to statins for the primary prevention of CVD,
however it was measured, appears to be sub-optimal. There was some evidence that the wide
variation of the number of adherent patients reflects the heterogeneity across studies with
respect to the characteristics of the sample and study design (Table 2). The length of follow-up
and type of adherence measure appeared to account for some of the variability observed across
studies (Fig 2). Quantitative synthesis of the data that met the conditions for a meta-analysis
revealed pooled estimates with high heterogeneity (I2>90%), therefore only the qualitative
synthesis is reported.
Table 1. Quality criteria for strength of evidence and conflicting evidence.
Strength of
evidencea
1 2 3 4 5 0
Quality 1 low quality
study
Several low quality
studies or 1 high quality
study
1 high quality study or
Several low quality
studies
1 high quality study and
Several low quality
studies
Several high
quality studies
Equivalent strength of
evidence (1–5) for the
presence or direction of
effect.
Requirement for
adjustment
No No No Yes Yes NA
Sample size Total
sample < 1000
Total sample < 1000 Total sample� 1000 Total sample� 1000 Total
sample� 1000
NA
https://doi.org/10.1371/journal.pone.0201196.t001
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Traditional cardiovascular risk factors
The standard components of the CVD risk scores (i.e. age, male gender, LDL-C levels, the
presence of comorbid diabetes and the presence of co-morbid hypertension) are used by phy-
sicians to decide who should be prescribed a statin for the primary prevention of a CV event.
Fig 1. PRISMA flow diagram of article selection process.
https://doi.org/10.1371/journal.pone.0201196.g001
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Table 2. Description of studies included in the review.
Study Population/ Country Adherence
measure
Design N Age
(years)�
%
female
Adherence
definition
Follow-
up
%
adherent
QA
score
Adjusted
ES
Stilley (2004)
[49]
Volunteer/ USA MEMS dose
& schedule
RCT 158 46.2
(8.7)
46.2 � 80% 6
months
22.8 10 no
Farsaei (2015)
[45]
Diabetes / Iran MPR Prospective
Cohort
158 56.4
(9.3)
66.4 � 80% 3
months
51.8 7 no
Halava (2014)
[46]
Population register /
Finland
PDC Prospective
Cohort
6458 24–75 77.9 � 80% 6
months
49.1 16 yes
Batal (2007)[35] HMO register / USA MPR Retrospective
cohort
3292 57.8
(10.9)
57.1 � 80% 1.5
years
41 13 yes
Bryson (2008)
[36]
HMO register / USA PDC Retrospective
Cohort
5473 64 (9.7) 2.4 � 80% 3
months
74 14 yes
PDC � 80% 1 year 64 14 yes
Perreault (2009)
[40]
HMO register / Canada MPR Retrospective
Cohort
242914 45–85 58 � 80% 1 year 61.6 13 no
Perreault
(2009a)[41]
HMO register / Canada MPR Retrospective
Cohort
55134 45–85 60 � 80% 3 years 61.6 13 no
Corrao (2010)
[37]
HMO register / Italy PDC Retrospective
cohort
90832 61.8
(11.1)
59.3 � 80% 5 years 19.6 13 no
Rublee (2012)
[42]
HMO register / USA PDC Retrospective
Cohort
79010 NP 46 � 75% 1 year 51.9 13 no
Slejko (2014)
[43]
Population register / USA PDC Retrospective
Cohort
11126 55.9
(10.3)
46.6 � 80% 1 year 70.2 13 no
Wallach-
Kildemoes
(2014)[44]
Population register /
Denmark
PDC Retrospective
Cohort
26397 40–64 100 � 80% 1 year 69.2 16 yes
PDC 24886 40–64 0 � 80% 1 year 63.8 16 yes
PDC 8765 65–84 0 � 80% 1 year 67.9 16 yes
PDC 15990 65–84 100 � 80% 1 year 69.2 16 yes
Halava (2015)
[38]
Population register /
Sweden
PDC Retrospective
cohort
5033 44–68 0 � 80% 4 years 82.2 15 yes
PDC 4232 44–68 100 � 80% 4 years 78.3 15 yes
Aarnio (2016)
[34]
Population register /
Finland
PDC Retrospective
cohort
116846 60.8
(7.8)
100 � 80% 1.5
years
50.5 16 yes
PDC 51590 58 (7.7) 0 � 80% 1.5
years
51.3 16 yes
Lavikainen
(2016)[39]
Population register /
Finland
PDC Retrospective
Cohort
42807 55–59 100 � 80% 1.5
years
53 13 no
Guthrie (2001)
[48]
Primary care research
register /USA
Self-report RCT 4548 58.0
(NP)
52.4 “Yes” 6
months
79.2 5 no
Mann (2007)
[47]
Veterans/ USA Self-report Prospective
Cohort
71 61 (12.6) 10 MAS <11 6
months
43 14 no
Harrison (2013)
[33]
HMO register / USA Self-report Cross-
sectional
98 59.3
(13.4)
46.9 Filled 1st
prescription
3
months
25.5 4 no
Braamskamp
(2015)[32]
Familial
hypercholesterolemia/
Netherlands
Self-report Cross-
sectional
169 24 (3.2) 54 MASRI VAS
�80
1
month
78.7 14 no
Al-Foraih
(2016)[31]
Hypercholesterolemia/
Kuwait
Self-report Cross-
sectional
200 51–60 68.5 MMAS
score� 6
NA 41 13 Yes
�Mean(SD) otherwise range; HMO; Health Maintenance Organisation; RCT = Randomised Controlled Trial; PDC = Proportion of days covered; MPR = Medication
Possession Ratio; MEMS = Medication Event Monitoring System; MMAS-8; Morisky Medication Adherence Scale MASRI VAS; Medication Adherence Self-Report
Inventory Visual Analogue Scale; MAS: Morisky Adherence Scale; QA score = Quality Assessment Score; ES = Effect size.
https://doi.org/10.1371/journal.pone.0201196.t002
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We considered these patient factors as potential predictors of adherence because the physician
may make the patient aware that possessing these characteristics increases their ten year risk
for a CV event.
Age-positively associates with statin adherence (Strength of evidence = 5). There is
strong evidence that older age predicts statin adherence. Four studies (three high quality &
one low quality), including a total of 662638 participants, that adjusted for confounders
[31,34,35,44] and six studies (Total N = 496921, two high quality & four low quality) with
unadjusted effects found adherence increased with older age [37,40,42,43,47]. One small
(N = 169) high quality study and one small low quality study (N = 158) found age did not
associate with adherence [32,45] (Fig 3). Braamskamp et al may have found a different effect
because they investigated adherence in a cohort of young adults with familial hypercholesterol-
emia; this population has an average age of 24 years, this is much younger than the typical pop-
ulation who commence statins [32]. Wallach-Kildemoes et al. found that the adjusted odds
of adherence increased by up to a factor of 2 per five year increase in age in their male and
female cohorts aged 40 to 65 years [44]. From the same cohort study the odds of being adher-
ent decreased by up to 60% per five year increase in age in the male and female cohorts aged
65–80 years.
Men are more adherent than women—Strength of evidence = 4. One large high quality
study that adjusted for other factors and four low quality studies with unadjusted effect
sizes (Total N = 301106), reported men were more adherent than women [34,35,37,42,43].
In one high quality and one low quality study women were more adherent than men (Total
N = 318952), but these effects were not adjusted for other factors [40,44]. Finally there was
Fig 2. Percentage of patients adherent to statins grouped by follow-up and adherence measure. MEMS; Medcation event monitoring system,
Pharmacy refill; medication possession ratio (MPR) or Proportion of days covered (PDC).
https://doi.org/10.1371/journal.pone.0201196.g002
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limited evidence that gender has no effect upon statin adherence from three studies (Total
N = 527, n high quality = 1) [31,32,45](Fig 4).
High cholesterol / Dyslipidemia does not associate with statin adherence—Strength of
evidence = 3. In one large high quality general population study the presence of dyslipidemia
was not associated with the odds of being adherent in the female or male cohorts [32]. Braams-
kamp et al. found, in a population of young adults with familial hypercholesterolemia, baseline
LDL-C levels were not associated with self-reported adherence over the past month (OR 0.90,
95%CI;0.70–1.19).
Diabetes associates with statin adherence—Strength of evidence = 4. Eight studies
examined the relationship between diabetes and being adherent [31,34,35,37,40,42,43,45].
There was strong evidence that that people with diabetes are more likely to adhere to statins,
four large studies including Aarnio et al. that adjusted for other confounders found that people
with diabetes or who used of antidiabetic medications had an increased odds of being adherent
compared to non-diabetics (Total N = 376694). There was moderate evidence that diabetes
does not associate with adherence from three low quality studies (Total N = 14576, mean QA
score = 11) and limited evidence that diabetes reduced the odds of being adherent (Total N
79010, QA score = 13) (Fig 5).
Hypertension/blood pressure associates with adherence—Strength of evidence = 5.
Qualitative synthesis of the evidence indicated that there is very strong evidence that hyperten-
sion positively associates with statin adherence even after adjusting for other factors (Total
N = 551094, n High quality = 2) [31,34,37,40,42], there was moderate evidence of no effect of
hypertension on statin adherence in women (Total N = 65256, QA score = 16) [34], and no
evidence of a negative effect (Fig 6). Aarnio et al. (2016) also noted that the odds of adherence
Fig 3. The relationship between age and statin adherence. �Wallach-Kildemoes; HMO: Health maintenance organisation; General: General
population register; FH: Familial hypercholesterolemia; HC: Hypercholesterolemia; QA: Quality assessment; Adj. ES: Adjusted effect size; RR: Relative
risk; OR: Odds ratio; MD: Mean difference.
https://doi.org/10.1371/journal.pone.0201196.g003
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to statins increased for every additional class of CV medications prescribed, and this effect was
observed in both men (OR 1.03, 95%CI; 1.0–1.06) and women (OR 1.04, 95%CI;1.01–1.08).
Being an ex-smoker associates with adherence—Strength of evidence = 3. Smoking sta-
tus was investigated in two studies. In one large high quality study being a current smoker (vs
being a non-smoker) did not predict being adherent (OR 1.01 (0.86–1.18)) (n = 6458, QA
score = 16), whilst in this same study being an ex-smoker predicted good adherence (OR 1.20,
95%CI;1.0–1.3) [46]. One small low quality study compared current smokers versus non-
smokers and former smokers grouped together and found a non-significant negative effect of
smoking (yes v no) (OR 0.69 95%CI: 0.23–2.07) (n = 200, QA score = 13) [31].
Socioeconomic factors
Low socioeconomic status indicated by lower levels of income, education and work status are
known to associate with CVD. One of the mechanisms through which this association may
occur is lower levels of adherence to medications such as stains.
Higher income associates with adherence and interacts with gender—Strength of evi-
dence = 5. Two high quality studies that adjusted for other confounders including socioeco-
nomic factors compared adherence across income quintiles [34,44]. Wallach-Kildemoes et al.
(2014) stratified their cohort by age and gender and then split their samples into quintiles of
income that took into account family composition; the exact income thresholds for each quin-
tile were not presented. Compared to participants in the lowest income quintile, participants
in the higher income quintiles were more likely to be adherent, after adjustment for age,
income, education and hypertension. This effect was observed in men and women of middle
and post-retirement age; the strongest effects were observed for men of middle age (OR 1.56,
Fig 4. The relationship between being male and statin adherence. �Wallach-Kildemoes; HMO: Health maintenance organisation; General: General
population register; HC: Hypercholesterolemia; QA: Quality assessment; Adj. ES: Adjusted effect size; RR: Relative risk; OR: Odds ratio.
https://doi.org/10.1371/journal.pone.0201196.g004
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95%CI; 1.54–1.56) [43]. Aarnio et al (2016) used the taxable income per year to calculate
income quintiles and used the wealthiest quintile as their reference category [33], in men there
was a strong positive effect of income on the odds of adherence; compared to men in the
wealthiest quintile men in succeeding lower income quintiles were less likely to adhere and the
strongest effect was observed with men in the poorest quintile (OR 0.74, 95%CI; 0.68–0.79).
The strength of these associations was attenuated in the cohort of women; only women in the
poorest quintile were less likely to be adherent compared to women in the highest income
quintile (OR 0.93, 95%CI; 0.86–1.00). These analyses adjusted for other socioeconomic and
clinical factors but not smoking status.
Higher level of education associates with statin adherence and interacts with gender—
Strength of evidence = 5. Four studies provided data on the level of education and statin
adherence [34,44,45,47]. In studies where more than 50% of the sample were male a higher
level of education increased the likelihood of adhering (OR 1.07, 95%CI;1.04–1.10), whereas in
studies where 50% or more of the sample were women a good education reduced the likeli-
hood of adhering to statins (OR 0.92, 95%CI; 0.89–0.95). These estimates included two studies
that were of high quality and adjusted for other confounders including socioeconomic factors
[34,44]. Aarnio et al. found that the likelihood of being adherent was lower for men if they had
a basic level or secondary level education compared to those with a degree [33]. Wallach-Kil-
demoes et al reported a similar positive effect in men who had 12 or more years of education
compared to those with 7–10 years or 10–12 years of education [43]. This effect attenuated
once income and age were controlled for in the analyses but remained for the most versus the
least educated men. The opposite effect was observed in women; increasing levels of education
were associated with a lower odds of being adherent, and these effects remained even after
Fig 5. The relationship between diabetes and statin adherence. HMO: Health maintenance organisation; General: General population register; HC:
Hypercholesterolemia; QA: Quality assessment; Adj. ES: Adjusted effect size; RR: Relative risk; OR: Odds ratio; MD: Mean difference.
https://doi.org/10.1371/journal.pone.0201196.g005
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controlling for other covariates, the strongest effect was observed in Finnish women aged 40–
64 years (OR 0.85, 95%CI; 0.85–0.85) (Fig 7).
The relationship between work status and statin adherence—Strength of evidence = 0.
Two large high quality studies and one small low quality study investigated the effect of work
on adherence [31,34,38]. Being in work reduced the likelihood of adhering to statins. In partic-
ular compared to employed people, retired people were 11% more likely to be adherent, and
this appears to be the case for both men and women after adjustment for other factors includ-
ing age and other comorbidities [34]. However, Halava et al. followed a Swedish cohort over
the transition from employment to retirement and captured the prevalence of non-adherence
[38]. Using a repeated measures design they found that adherence to statins was lower after
retirement (PR 0.85, 95%CI; 0.80–0.88). Halava et al. adjusted for the calendar year, time in
study, and age at retirement, but not for other factors such as the number or type of co-mor-
bidities that may have confounded this relationship. Given there were only two studies with
conflicting findings further research is needed. Simple comparisons of retired and employed
groups should be avoided since they may be confounded by age, which strongly associates
with both statin adherence and retirement.
The effect of region on adherence—Strength of evidence = 4. Four studies provided
data on adherence across different regions including one large high quality study that adjusted
for confounders and several studies with unadjusted effects Several studies looked at adherence
in regions within countries and observed significant differences across regions of the USA,
Finland and Kuwait [34,42,43,45]. The effect sizes observed suggest the effect of living in a par-
ticular place could reduce the odds of adhering by between 10 to 50% (Table 3). The reason for
these differences could be variations in health, health services or socioeconomic factors.
Fig 6. The relationship between Hypertension and statin adherence. �Wallach-Kildemoes; HMO: Health maintenance organisation; General:
General population register; QA: Quality assessment; Adj. ES: Adjusted effect size.
https://doi.org/10.1371/journal.pone.0201196.g006
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Without further knowledge of the economic and health profiles of these regions these data are
difficult to interpret.
Other demographic factors
Three studies provided data on other demographic factors [34,35,47].
Being married negatively associates with statin adherence—Strength of evidence = 3.
Aarnio et al. reported that, compared to single men, married men after adjustment for other
covariates were less likely to adhere to statins (OR 0.85, 955CI;0.80–0.91), as were divorced
men (OR 0.61 95%CI; 0.56–0.67) and widowed men (OR 0.79, 95%CI; 0.69–0.79). The effects
were very similar in the cohort of women [34]. The finding that married men and women are
less adherent than single men and women is surprising, since married individuals generally
benefit from spousal support that should ease not hinder adherent behaviour, therefore further
research is required.
Racial background associates with adherence—Strength of evidence = 3. The effect of
race on statin adherence was investigated in two US studies. In adjusted analyses Mann et al.
reported being Hispanic American reduced the odds of adherence compared to being White
American (OR 0.26, 95%CI;0.07–1.0) [47]. Batal et al reported the relative risk of being His-
panic American on statin adherence and, after adjustment for demographic and clinical factors
and treatment costs, being Hispanic reduced the likelihood of adherence (RR 0.77, 95%CI;
0.72–0.84). Batal et al. also reported the likelihood of Black Americans adhering compared to
White Americans was lower (RR 0.77, 95%CI; 0.70–0.86) [35]. These findings can be inter-
preted within the context of previous findings that in the US Black and Hispanic Americans
face more barriers to adhering to statins such as lower levels of insurance and access to care.
Fig 7. The sex dependent relationship between education and statin adherence. �Wallach-Kildemoes; HMO: Health maintenance organisation;
General: General population register; QA: Quality assessment; Adj. ES: Adjusted effect size; RR: Relative risk; OR: Odds ratio.
https://doi.org/10.1371/journal.pone.0201196.g007
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Table 3. Study characteristics and the investigated predictors of the included articles ordered by study design.
Reference (Year) Country Covariates in
multivariable models
Factors associated with good adherence Effect size (Confidence
Interval)
Factors not associated with good
adherence
Cross sectional
Al-Foraih & Somerset (2016) [31]
Kuwait
Age
Gender
Smoking
Diabetes
Traditional CVD risk factors
Age OR 1.05 (1.01–1.09)
OR 1.35 (2.78, 0.64)a Being male
OR 0.69 (0.23–2.07) Smoker (yes v no)
Diabetes OR 2.38 (1.33–4.35) a
Hypertension OR 2.00 (NP) a,b
Socioeconomic Factors
OR 0.62 (NP)b Working (no v yes)
ref Region: Al-Asimah
OR 1.07 (NP)b Hawalli
OR 1.21 (NP)b Al-Farwaniya
OR 0.73 (NP)b Mubarak Al-Kabir
Psychological factors
OR 0.98 (NP)b DASS Depression
OR 0.96 (NP)b DASS Anxiety
OR 0.99 (NP)b DASS Stress
Treatment related factors
Statin duration OR 1.04 (NP)b
ref Atorvastatin
OR 0.29(NP)b Rosuvastatin
OR 1.64 (NP)b Simvastatin
Braamskamp et al (2015)[32]
Netherlands
All variables Entered into
backward stepwise
regression—adjusted
effects not presented
Traditional CVD related factors
OR 1.11(0.97–1.22)b Age
OR 1.28 (0.63–2.61)b Male gender
OR 0.90(0.70–1.19)b LDL-C (pre-statin)
OR 0.96(0.89–1.03)b BMI
OR 1.20 (0.58–2.46)b CVD 1st degree relative
Treatment related factors
OR 1.39 (0.49–3.90)b Use of concurrent meds
OR 1.66 (0.77–3.58)b Initiation statins < puberty
OR 0.54 (0.31–1.87)b Side effects
Harrison et al. (2013)[33] USA NA NA NA NA
Retrospective
Aarnio et al. (2016)[34] Finland Adjusted for all baseline
characteristics: CVD risks,
socioeconomic
demographic,
comorbidities, treatment
related and cost related
factors, and year of statin
initiation
Traditional CVD related factors
Gender (male v female) OR 1.06 (1.03–1.09)b,c
Male cohort
Age (years): 45–49 Ref
50–54 OR 1.16 (1.10–1.23)a
55–59 OR 1.25 (1.18–1.33)a
60–64 OR 1.25 (1.18–1.35)a a
65–69 OR 1.27 (1.16–1.39)a
�70 OR 1.20 (1.10–1.33))a
Diabetes mellitus OR 1.14 (1.09–1.20)a
Hypertension OR 1.09 (1.02–1.1.5)a
OR 1.05 (0.89–1.23)a Dyslipidemia
Num. of CV meds (per additional class) OR 1.03 (1.00–1.06)a
(Continued)
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Table 3. (Continued)
Reference (Year) Country Covariates in
multivariable models
Factors associated with good adherence Effect size (Confidence
Interval)
Factors not associated with good
adherence
Socioeconomic Factors
Income (€/year):�31400 Ref
�10200 OR 0.74 (0.68–0.79)a
10300–15300 OR 0.80 (0.75–0.85)a
15400–22000 OR 0.84 (0.79–0.89)a
22100–31300: OR 0.94 (0.90–1.0)a
Education: Higher degree Ref
Basic education OR 0.92 (0.88–0.96)a
Secondary education OR 0.91 (0.86–0.95)a
Labour status: Employed Ref
Unemployed OR 0.98 (0.92–1.05)a
Retired OR 1.11 (1.05–1.19)a
Out of labour market OR 0.90 (0.78–1.04)a
Marital Status: Single Ref
Married OR 0.85 (0.80-.91)a
Divorced OR 0.61 (0.56-.67))a
Widowed OR 0.79 (0.69-.92)a
Region: Southern Ref
Southwestern OR 0.90 (0.85–0.95)a
Central OR 0.92 (0.88–0.96)a
Eastern OR 0.98 (0.93–1.03)a
Northern OR 0.83 (0.79–0.88)a
Co-morbidities:
OR 1.02 (0.97–1.06)a CCI (per additional point)
OR 1.14 (1.03–1.27)a Atrial fibrillation
OR 0.81 (0.64–1.02)a Obesity
OR 1.02 (0.90–1.16)a Cancer
OR 1.10 (0.93–1.28)a Cardiac insufficiency
COPD & asthma OR 0.85 (0.79–0.91)a
OR 0.94 (0.83–1.08)a Rheumatoid arthritis
OR 1.27 (0.89–1.79)a Renal Insufficiency
Alcoholism/narcomania OR 0.76 (0.63–0.92)a
Dementia OR 2.17 (1.52–3.23)a
Depression OR 0.85 (0.79–0.93)a
Mental Disorder OR 1.41 (1.25–1.59)a
No. of hospital days: 0 Ref
1–4 OR 0.94 (0.90–0.98)
5–10 OR 0.93 (0.85–0.99)a
OR 0.93 (0.83–1.05)a 11–20
OR 1.05 (0.90–1.22)a �21
Use of NSAIDs OR 0.88 (0.83–0.91)a
OR 0.99 (0.98–1.01)a Per additional medicine
Medication Costs
Total out-of-pocket costs (per additional
€50)
OR 1.12 (1.10–1.15)a
Co-payment dispensation (euro cents/
tablet) <20
Ref.
(Continued)
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Table 3. (Continued)
Reference (Year) Country Covariates in
multivariable models
Factors associated with good adherence Effect size (Confidence
Interval)
Factors not associated with good
adherence
20-<30 OR 0.90 (0.79–1.02)a
30-<60 OR 0.77 (0.70–0.85)a
60-<70 OR 0.73 (0.66–0.81)a
70-<90 OR 0.61 (0.55–0.68)a
90-<120 OR 0.53 (0.47–0.59)a
�120 OR 0.38 (0.32–0.45)a
Treatment related Factors
Type of statin: Simvastatin Ref
Lovastatin OR 0.84 (0.72–0.98)a
OR 0.99 (0.89–1.01)a Pravastatin
Fluvastatin OR 1.12 (1.04–1.22)a
Atorvastatin OR 1.30 (1.22–1.37)a
Rosuvastatin OR 1.45 (1.33–1.59)a
Statin dose intensity: Low1 Ref
Moderate2 OR 0.89 (0.84–0.94)a
High3 OR 0.70 (0.54–0.92)a
Aarnio et al. (2016)[34] Finland Adjusted for all baseline
characteristics: CVD risk,
socioeconomic
demographic,
comorbidities, treatment
related and cost related
factors, and year of statin
initiation
Traditional CVD risk related factors
Female cohort
Age (years): 45–49 Ref
50–54 OR 1.08 (1.00–1.15)a
55–59 OR 1.22 (1.14–1.30)a
60–64 OR 1.22 (1.14–1.32)a
65–69 OR 1.23 (1.14–1.35)a
�70 OR 1.27 (1.16–1.39)a
Diabetes mellitus OR 1.19 (1.12–1.27)a
OR 1.03 (0.87–1.22)a Dyslipidemia
OR 1.01 (0.96–1.06)a Hypertension
Num. of CV Meds.(per additional class) OR 1.04 (1.01–1.08)a
Socioeconomic Factors
Income (€/year):�31400 Ref
�10200 OR 0.93 (0.86–1.00)a
10300–15300 OR 0.95 (0.88–1.02)a
15400–22000 OR 1.00 (0.93–1.06)a
22100–31300: OR 0.98 (0.93–1.05)a
Education: Higher degree Ref
Basic education OR 1.06 (1.01–1.11)a
Secondary education OR 1.03 (0.98–1.09)a
Labour status: Employed Ref
Unemployed OR 1.06 (1.00–1.14)a
Retired OR 1.11 (1.05–1.18)a
Out of labour market OR 0.94 (0.84–1.05)a
Marital Status: Single Ref
Married OR 0.85 (0.79–0.90)a
Divorced OR 0.68 (0.64–0.74)a
Widowed OR 0.78 (0.72–0.85)a
Region: Southern Ref
Southwestern OR 0.93 (0.88–0.97)a
Central OR 1.00 (0.96–1.04)a
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Table 3. (Continued)
Reference (Year) Country Covariates in
multivariable models
Factors associated with good adherence Effect size (Confidence
Interval)
Factors not associated with good
adherence
Eastern OR 1.08 (1.03–1.12)a
Northern OR 0.90 (0.85–0.95)a
Co-morbidities:
OR 1.01 (0.96–1.05)a CCI (per additional point)
Obesity OR 0.76 (0.61–0.93)a
Atrial fibrillation OR 0.90 (0.80–1.02)a
OR 0.99 (0.84–1.17)a Cardiac insufficiency
Alcoholism/narcomania OR 0.53 (0.41–0.69)a
Dementia OR 1.41 (1.10–1.82)a
Depression OR 0.91 (0.85–0.95)a
Mental Disorder OR 1.35 (1.23–1.49)a
Cancer OR 1.11 (1.00–1.23)a
COPD & asthma OR 0.82 (0.78–0.86)a
OR 1.41 (0.96–2.04)a Renal Insufficiency
Rheumatoid arthritis OR 0.90 (0.82–0.99)a
No. of hospital days: 0 Ref
1–4 OR 0.93 (0.89–0.96)a
5–10 OR 0.91 (0.85–0.97)a
11–20 OR 0.90 (0.81–1.00)a
�21 OR 1.02 (0.89–1.16)a
Use of NSAIDs OR 0.92 (0.88–0.95)a
Hormone therapy OR 1.09 (1.05–1.12)a
OR 0.99 (0.98–1.01)a Per additional medicine
Cost related Factors
Total out-of-pocket costs (per additional
€50)
OR 1.12 (1.11–1.15)a
Co-payment dispensation (euro cents/
tablet) <20
Ref
20-<30 OR 0.75 (0.67–0.83)a
30-<60 OR 0.68 (0.63–0.68)a
60-<70 OR 0.68 (0.63–0.68)a
70-<90 OR 0.57 (0.52–0.63)a
90-<120 OR 0.48 (0.43–0.53)a
�120 OR 0.37 (0.32–0.45)a
Treatment related Factors
Type of statin: Simvastatin Ref
Lovastatin OR 0.86 (0.76–0.97)a
Pravastatin OR 0.99 (0.90–1.08)a
Fluvastatin OR 1.15 (1.11–1.22)a
Atorvastatin OR 1.16 (1.11–1.22)a
Rosuvastatin OR 1.32 (1.23–1.43)a
Statin dose intensity: Low1 Ref
Moderate2 OR 0.90 (0.85–0.85)a
High3 OR 0.61 (0.45–0.82)a
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Table 3. (Continued)
Reference (Year) Country Covariates in
multivariable models
Factors associated with good adherence Effect size (Confidence
Interval)
Factors not associated with good
adherence
Batal et al. (2007)[35] USA Gender
Age
Race/ethnicity
Insurance status
Co-payment
Number of comorbidities
Traditional CVD risk related factors
Male gender RR 1.09 (1.02–1.16)a
Age (per 10 yr increase) RR 1.07 (1.03–1.10)a
OR 0.90 (0.79–1.04) Use of diabetics
Co-morbidities:
Num. of Comorbidities RR 1.04 (1.03–1.06)a
Demographic factors:
Race: Whited Ref
Black RR .77 (0.70–0.86)a
Hispanic RR .77 (0.70–0.86)a
RR 1.02 (0.91–1.16)a Other
Treatment related Factors
60 versus 30 day supply RR 1.40 (1.27–1.55)a
Cost related Factors
OR 1.09 (0.94–1.26) Insurance
OR 1.0 (0.92–1.24) Co-payment
Corrao et al. (2010)[37] Italy None Traditional CVD risk related factors
Male gender OR 1.23 (1.19–1.27)b,c
Age (years) MD 1.7 (1.50–1.90)c,d
Antidiabetics (yes) OR 0.26 (0.24–0.29)b,c
Co-morbidities:
CCI score = 0 Ref
1 OR 2.3 (2.0–2.6) c,d
2 OR 2.30 (2.17–2.44)b,c
Antihypertensives OR 0.07 (0.07–0.08)b,c
Digitalis or organic nitrates OR 0.25 (0.24–0.27)b,c
Other cardiac drugs OR 0.23 (0.24–0.25)b,c
Treatment related Factors
Type of statin: Simvastatin Ref
OR 1.02 (0.97–1.08) b,c Pravastatin
Fluvastatin OR 2.3 (2.17–2.44) b,c
Atorvastatin OR 2.58 (2.45–2.71) b,c
Statin switching (yes) OR 0.52 (0.47–0.57) b,c
Bryson et al. (2008)[36] USA Age
Gender
Marital status
Race/Ethinicity
Education
Number of Medications
Smoking status
Depression
Alcohol misuse: None Ref
OR 0.95 (0.82–1.10)d Low drinker
OR 1.03 (0.83–1.27)d Mild misuse
OR 1.00 (0.72–1.38)d Moderate misuse
Severe misuse OR 0.68 (0.48–0.96)d
Alcohol misuse: None Ref
OR 0.99 (0.90–1.09)d Low drinker
OR 0.99 (0.86–1.14)d Mild misuse
OR 1.00 (0.81–1.24)d Moderate misuse
Severe misuse OR 0.73 (0.56–0.96)d
Halava et al. (2015)[38] Sweden Time, calendar year, age at
retirement, primary
prevention�time
Socioeconomic Factors
Retirement (adj. for age) PR 0.85(0.80–0.88)d
Retirement (adj. for age) PR 0.85(0.81–0.90)d
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Table 3. (Continued)
Reference (Year) Country Covariates in
multivariable models
Factors associated with good adherence Effect size (Confidence
Interval)
Factors not associated with good
adherence
Lavikainen et al. (2016)[39] Finland None Traditional CVD risk related factors
Age 45–49 years Ref
50–54 years OR 1.11 (1.03–1.19)b,c,e
55–59 years OR 1.30 (1.22–1.39) b,c,e
60–64 years OR 1.33 (1.24–1.42) b,c,e
OR 0.87 (0.72–1.05) b,c,e Dyslipidemia
Diabetes (yes v no) OR 1.21 (1.14–1.29) b,c,e
Use of insulin (yes v no) OR 1.13 (1.01–1.25) b,c,e
Hypertension OR 1.13 (1.09–1.18) b,c,e
OR 1.00 (0.77–1.32) b,c,e Heart failure
Number of CVD meds- 0 Ref
1 OR 1.18 (1.13–1.23) b,c,e
2 OR 1.19 (1.12–1.25) b,c,e
3–6 OR 1.21 (1.11–1.31) b,c,e
Socioeconomic Factors
Ref Income (€) �11,200
OR 1.01 (0.96–1.07) b,c,e 11,300–18,700
OR 0.99 (0.94–1.05) b,c,e 18,800–25,400
OR 1.00 (0.95–1.06) b,c,e �25,500
Region: Helsinki Ref
Turku OR 0.93 (0.88–0.99) b,c,e
OR 1.01 (0.95–1.06) b,c,e Tampere
Kuopio OR 1.06 (1.0–1.11) b,c,e
Oulo OR 0.82 (0.77–0.87) b,c,e
Education: Higher degree Ref
Basic level OR 1.05 (1.00–1.11)b,c,e
OR 0.98 (0.93–1.03) b,c,e Secondary level
Marital status-married Ref
Divorced OR 0.82 (0.78–0.86) b,c,e
Unmarried OR 1.10 (1.03–1.17) b,c,e
Labour status- employed Ref
Unemployed OR 1.05 (1.00–1.11) b,c,e
Retired OR 1.16 (1.11–1.21) b,c,e
OR 0.95 (0.86–1.04) b,c,e Out of labour market
Comorbidities˚
CCI�1 OR 1.08 (1.00–1.16) b,c
Cancer OR 1.15 (1.04–1.27)b,c,e
OR 0.96 (0.85–1.09) b,c,e Cardiac arrhythmia
OR 1.05 (0.99–1.11) b,c,e Respiratory diseases
OR 1.02 (0.90–1.14) b,c,e Rheumatoid Arthritis
Alcohol-related diseases OR 0.62 (0.48–0.81) b,c,e
OR 1.05 (0.99–1.11) b,c,e Depression
Mental Disorders OR 1.36 (1.21–1.53 b,c,e
OR 1.01 (0.88–1.15) b,c Anxiolytics, hypnotics
0.90 (0.85–1.03) b,c Corticosteroids
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Table 3. (Continued)
Reference (Year) Country Covariates in
multivariable models
Factors associated with good adherence Effect size (Confidence
Interval)
Factors not associated with good
adherence
NSAID use OR 0.96 (0.93–1.00) b,c,e
Hormone therapy OR 1.15 (1.11–1.20) b,c,e
Number of meds.
1–2 Ref
3–5 OR 1.08 (1.04–1.14) b,c
6–31 OR 1.23 (1.17–1.29) b,c
Number of in-hospital days– 0 Ref
1–2 OR 0.90 (0.86–0.95) b,c,e
3–6 OR 0.91 (0.86–0.97) b,c,e
OR 0.97 (0.89–1.04) b,c,e 8–321
Treatment related Factors
Type of statin:
Simvastatin Ref
Lovastatin OR 0.80 (0.69–0.93) b,c,e
Pravastatin OR 0.65 (0.60–0.71) b,c,e
Fluvastatin OR 1.09 (1.01–1.17) b,c,e
Rosuvastatin OR 1.53 (1.37–1.80) b,c,e
OR 1.01 (0.96–1.05) b,c,e Atorvastatin
Year statin initiated-2001 Ref
2002 OR 1.06 (1.00–1.12) b,c
2003 OR 1.17 (1.10–1.23) b,c
2004 OR 1.34 (1.27–1.41) b,c
Stain dosing- Lowa Ref
Moderateb OR 0.92 (0.89–0.96) b,c,e
Highc OR 0.47 (0.34–0.64) b,c,e
Perrault et al. (2009)[40] Canada None Traditional CVD risk related factors
Age (years) MD 0.5 (0.42–0.58)b,f
Male gender OR 0.96 (0.94–0.97) b,c
Hypertension OR 1.59 (1.56–1.62) b,c
Diabetes OR 1.39 (1.36–1.42) b,c
Socioeconomic Factors
Social assistance OR 1.17 (1.38–1.47) b,c
Comorbidities
Chronic disease score (�4) OR 1.43 (1.14–1.20)b,c
Respiratory disease OR 1.05 (1.01–1.08) b,c
Use of antidepressants OR 1.21 (1.17–1.24) b,c
Use of anxiolytics0.25 OR 1.20 (1.17–1.24) b,c
Perrault et al. (2009a)[41] Canada None Traditional CVD risk related factors
Age (years) MD 1.0 (0.84–1.16)b,f,g
Male gender OR 0.96 (0.93–0.99) b,c,g
Hypertension OR 1.35 (1.31–1.40) b,c,g
Diabetes OR 1.31 (1.27–1.36) b,c,g
Socioeconomic Factors
Social assistance OR 1.15 (1.10–1.20) b,c,g
Comorbidities
Chronic disease score�4 OR 1.09 (1.05–1.14) b,c,g
Use of antiplatelets OR 1.23 (1.18–1.30) b,c,g
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Table 3. (Continued)
Reference (Year) Country Covariates in
multivariable models
Factors associated with good adherence Effect size (Confidence
Interval)
Factors not associated with good
adherence
Treatment related Factors
Type of statin:
Simvastatin Ref
Lovastatin OR 7.59 (6.71–8.58) b,c
Pravastatin OR 0.05 (0.05–0.06) b,c
Fluvastatin OR 0.72 (0.64–0.81) b,c
Rosuvastatin OR 0.68 (0.59–0.78) b,c
OR 0.92 (0.83–1.03) b,c Atorvastatin
Rublee et al. (2012)[42] USA None Traditional CVD risk related factors
Age (years) MD 2.3 (2.19–2.41)b,f
Male gender OR 1.04 (1.02–1.08) b,c
Hypertension OR 1.21 (1.18–1.25) b,c
Diabetes OR 0.86 (0.84–0.89) b,c
Use of beta blockers OR 1.34 (1.29–1.39) b,c
Use of ACE inhibitors OR 1.37 (1.32–1.41) b,c
Use of ARBs OR 1.24 (1.18–1.30) b,c
Use of Diuretics OR 1.27 (1.23–1.32) b,c
Use of anticoagulants OR 1.41 (1.29–1.55) b,c
Use of antiplatelet agents OR 1.05 (0.95–1.15) b,c
Use of vasodilators OR 1.11 (0.96–1.28) b,c
Use of digitalis OR 3.12 (2.67–3.63) b,c
Socioeconomic Factors
Region: Midwest Ref
Northeast OR 0.87 (0.83–0.91) b,c
Southeast OR 0.67 (0.65–0.70) b,c
South OR 0.68 (0.65–0.70) b,c
West OR 1.08 (1.03–1.13) b,c
Comorbidities
CCI = 0 Ref
1 OR 1.06 (1.01–1.18) b,c
2 OR 1.09 (1.05–1.13) b,c
3 OR 0.75 (0.70–0.80) b,c
OR 0.98 (0.92–1.04) b,c �4
Obesity OR 0.83 (0.78–0.88) b,c
OR 1.01 (0.96–1.06) b,c Depression
COPD OR 1.21 (1.12–1.31) b,c
Dementia OR 2.00 (1.36–2.94) b,c
Chronic Kidney Disease OR 1.14 (0.97–1.35) b,c
Cancer OR 1.34 (1.26–1.43) b,c
Medication Beliefs/behaviours
General physical exam OR 1.20 (1.17–1.23) b,c
Bone mineral density test OR 1.36 (1.28–1.44) b,c
Screening Mammography OR 1.53 (1.47–1.60) b,c
Papanicolaou test OR 1.16 (1.11–1.21) b,c
PSA testing OR 1.17 (1.13–1.22) b,c
Fecal occult blood tests OR 1.09 (1.05–1.13) b,c
Influenza vaccinations OR 1.31 (1.26–1.36) b,c
Pneumococcal vacc. OR 1.31 (1.19–1.43) b,c
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Table 3. (Continued)
Reference (Year) Country Covariates in
multivariable models
Factors associated with good adherence Effect size (Confidence
Interval)
Factors not associated with good
adherence
Cost related Factors
Health plan type:
Point of service Ref
Preferred provider OR 1.09 (1.00–1.20) b,c
OR 1.00 (0.97–1.03) b,c Health maintenance
Exclusive provider OR 0.51 (0.48–0.54) b,c
Indemnity OR 2.05 (1.89–2.23) b,c
Other OR 0.68 (0.62–0.75) b,c
Slejko et al. (2014)[43] USA None Traditional CVD risk related factors
OR 1.14 (1.05–1.24) b,c Gender
Age: over 65 years old OR 1.19 (1.03–1.37) b,c
OR 1.03 (0.91–1.17) b,c History of diabetes
History of hypertension OR 1.16 (1.04–1.28)
Socioeconomic Factors
Region: Midwest Ref
Northeast OR 0.82 (0.72–0.93) b,c
South OR 0.68 (0.59–0.79) b,c
West OR 0.79 (0.65–0.95) b,c
Treatment related Factors
Prescribing Physician: General
practitioner
Ref
OR 0.92 (0.80–1.06) b,c Internist
Cardiologist OR 3.91 (3.07–4.98) b,c
OR 0.93 (0.83–1.06) b,c Other/unknown
Cost related Factors
Ref Plan type: Commercial
OR 0.84 (0.67–1.05) b,c Medicare
OR 1.07 (0.44–2.58) b,c Medicaid
OR 1.46 (0.1–1.2) b,c Other
Wallach-Kildemoes et al. (2014)[44]
Denmark
Age
Income
Education
Hypertension
Men aged 40–64 years
Traditional CVD risk related factors
Age (years): 40–44 Ref
45–49 OR 1.16 (1.16–1.16)a
50–54 OR 1.43 (1.43–1.43)a
55–59 OR 1.54 (1.54–1.54)a
60–64 OR 1.85 (1.85–1.89)a
Hypertension OR 1.43 (1.41–1.43)a
Socioeconomic Factors
Income: 1. Lowest Ref
2 OR 1.27 (1.27–1.27)a
3 OR 1.41 (1.41–1.41)a
4 OR 1.59 (1.56–1.59)a
5. Highest OR 1.56 (1.54–1.56)a
Education (years): 7–10 Ref
OR 1.00 (1.00–1.00)a 10–12
� 12 OR 1.03 (1.03–1.03)a
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Table 3. (Continued)
Reference (Year) Country Covariates in
multivariable models
Factors associated with good adherence Effect size (Confidence
Interval)
Factors not associated with good
adherence
Age
Income
Education
Hypertension
Women aged 40–64 years
Traditional CVD risk related factors
Age (years): 40–44 Ref
45–49 OR 1.33 (1.32–1.33)a
50–54 OR 1.61 (1.61–1.64)a
55–59 OR 1.82 (1.82–1.85)a
60–64 OR 1.96 (1.96–1.96)a
Hypertension OR 1.33(1.33–1.33)a
Socioeconomic Factors
Income: 1. Lowest Ref
2 OR 1.16 (1.16–1.16)a
3 OR 1.30 (1.28–1.30)a
4 OR 1.32 (1.32–1.32)a
5. Highest OR 1.27 (1.27–1.27)a
Education (years): 7–10 Ref
10–12 OR 0.90 (0.90–0.90)a
� 12 OR 0.85 (0.85–0.85)a
Age
Income
Education
Hypertension
Men aged 65–84 years
Traditional CVD risk related factors
Age (years): 65–79 Ref
70–75 OR 1.01 (1.01–1.01)a
75–79 OR 0.92 (0.92–0.93)a
80–84 OR 0.63 (0.63–0.63)a
Hypertension OR 1.47 (1.47–1.47)a
Socioeconomic Factors
Income: 1. Lowest Ref
2 OR 1.22 (1.22–1.22)a
3 OR 1.22 (1.22–1.22)a
4 OR 1.30 (1.30–1.30)a
5. Highest OR 1.37 (1.37–1.37)a
Education (years): 7–10 Ref
10–12 OR 0.99 (0.99–0.99)a
� 12 OR 1.03 (1.03–1.03)a
Age
Income
Education
Hypertension
Women aged 65–84 years
Traditional CVD risk related factors
Age (years): 65–79 Ref
70–75 OR 0.86 (0.85–0.86)a
75–79 OR 0.65 (0.65–0.65)a
80–84 OR 0.61 (0.61–0.62)a
Hypertension OR 1.27 (1.27–1.27)a
Socioeconomic Factors
Income 1. Lowest Ref
2 OR 1.14 (1.14–1.14)a
3 OR 1.09 (1.08–1.09)a
4 OR 1.09 (1.09–1.09)a
5. Highest OR 1.05 (1.05–1.06)a
Education (years): 7–10 Ref
10–12 OR 0.91 (0.90–0.91)a
� 12 OR 0.91 (0.90–0.91)a
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Table 3. (Continued)
Reference (Year) Country Covariates in
multivariable models
Factors associated with good adherence Effect size (Confidence
Interval)
Factors not associated with good
adherence
Prospective cohort studies
Farsaei et al. (2015)[45] Iran None Traditional CVD risk related factors
OR 1.37 (0.58–3.22) Female gender
MD 2.6 (-0.47–5.67)b,f Age (years)
Socioeconomic Factors
Education level:
Ref Illiterate
OR 0.96 (0.35–2.67)b,c Primary
OR 0.84 (0.26–2.70) b,c Secondary
OR 0.99 (0.25–3.95) b,c Degree or higher
Comorbidities
Num. of medications MD 1.4 (0.98–1.82)b,f
Lifestyle Factors
MD -0.1 (-.1.69–1.49)b,f BMI
Halava et al. (2014)[46] Finland Gender, age Education,
region of birth, Marital
status, Cancer Depression,
Self-rated health
Traditional CVD risk related factors
Smoking -None Ref
Ex-smoker OR 1.20 (1.0–1.3)a
OR 1.01 (0.86–1.18)a Current smoker
Lifestyle factors
BMI <25 Ref
BMI 25–29.9 OR 0.88 (0.79–0.98)a
BMI �30 OR 0.86 (0.74–0.99)a
Ref Alcohol use: None
OR 0.92 (0.79–1.06)a Moderate
OR 0.88 (0.70–1.11)a High
OR 0.99 (0.71–1.23)a Extreme drinking (yes)
Ref Physical activity: Low
OR 0.99 (0.87–1.12)a,b,c Moderate
OR 1.00 (0.89–1.13) a,b,c Active
Ref Num. of risks: 0
OR 0.93 (0.85–1.04)a 1–2
OR 1.15 (1.52–0.87)a 3–4
Mann et al. (2007)[47] USA None Traditional CVD risk related factors
Age�50 years OR 6.65 (1.16–37.88) b,c
OR 1.45 (0.44–4.78) b,c Treated for hypertension
Socioeconomic Factors
OR 0.30 (0.06–1.58) b,c Race–Hispanic
OR 0.34 (0.06–1.87) b,c Some college
Comorbidities
OR 1.76 (0.42–7.34) b,c Has comorbidity
Medication Beliefs/behaviours
Had cholesterol check OR 4.75(1.17–19.24) b,c
OR 3.31 (0.73–13.76) b,c Taking BP pills
OR 0.34 (0.08–1.43) b,c Learnt more diet changes
Risk of MI < average OR 0.15 (0.04–0.61) b,c
OR 0.94 (0.05–2.18) b,c Do not worry about chol.
OR 4.51 (0.80–21.82) b,c Pills cure high chol.
OR 0.20 (0.04–1.08) b,c Will take pill rest of life
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Table 3. (Continued)
Reference (Year) Country Covariates in
multivariable models
Factors associated with good adherence Effect size (Confidence
Interval)
Factors not associated with good
adherence
Do not expect to take statin rest of life OR 0.20 (0.05–0.86) b,c
OR 0.94 (0.24–3.67) b,c Do not need pill
OR 0.65 (0.15–3.67) b,c Taking pill same or harder than diet
control
OR 0.89 (0.25–3.10) b,c Have concerns (statins)
OR 0.31 (0.07–1.31) b,c The pill may be harmful
All variables in univariate
analyses with p<0.2
entered into stepwise
regression
Traditional CVD risk related factors
Age�50 years OR 4.2 (1.1–15.8) a
Socioeconomic Factors
Race–Hispanic OR 0.26 (0.07–1.0) a
Medication Beliefs/behaviours
Plan to use statins <6 mo. OR 0.28 (0.11–0.71)a
Risk of MI < average OR 0.32 (0.11–0.91) a
Statin may be harmful OR 0.40 (0.16–1.0) a
RCT
Guthrie (2001)[48] USA None Medication Beliefs/behaviours
Seeing physician OR 1.25 (1.07–1.45) b,c
Changed eating habits OR 1.59 (1.35–1.88) b,c
OR 1.18 (0.99–1.39) b,c Lost weight
Increased physical activity OR 1.53 (1.28–1.82) b,c
OR 1.25 (0.97–1.62) b,c Tried to quit smoking
Improved BP control OR 1.43 (1.21–1.70) b,c
OR 1.19 (0.89–1.58) b,c Improved diabetes control
Stilley et al. (2004)[49] USA Psychological distress, IQ
Attention, Concs. Mental
Flexibility/ Perceptual
organization.
Conscientiousness (Concs.) B .24 (NP)b
Anxiety B-0.16 (NP)b
Depression B-0.24 (NP)b
Estimated IQ B 0.25 (NP)b
Attention B-0.16 (NP)b
Mental Flexibility B-0.21 (NP)b
Visuospatial/ construction B-0.21 (NP)b
B-0.05 (NP)b Neuroticism
B 0.03 (NP)b Extroversion
B-0.08 (NP)b Openness
B 0.03 (NP)b Agreeableness
B 0.06 (NP)b Verbal learning
B 0.03 (NP)b Verbal Recall
B 0.03 (NP)b Nonverbal memory
Conscientiousness B 0.47 (NP)
Estimated IQ B 0.22 (NP)
B -0.05 (NP) Psychological distress
B 0.07 (NP) IQ�Conscientiousness
SEP: Socioeconomic position; CCI: Charlson Comorbidity Index;
aEffect size inverted to predict adherence;
bUnadjusted analyses;
ccalculated from proportions;
dcalculated from proportion estimates;
epredictors from a subsample of Aarnio et al.;
fcalculated from means
gpredictor from a subsample of Perrault 2009; MMAS-8; Morisky Medication Adherence Scale; DASS; Depression, Anxiety and Stress Scale; MASRI VAS; Medication
Adherence Self-Report Inventory Visual Analogue Scale; MARS: Medication Adherence Report Scale; MAS: Morisky Adherence Scale;
1Fluvastatin 20–40mg, lovastatin 20mg, pravastatin 10–20mg, simvastatin 5–10mg;
2Atorvastatin 10–20mg, fluvastatin 80mg, lovastatin 40mg, pravastatin 40mg, rosuvastatin 10mg, simvastatin 20–40mg;
3Atorvastatin 40–80mg, rosuvastatin 20–40mg, simvastatin 60-80mg.
https://doi.org/10.1371/journal.pone.0201196.t003
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Given the increased prevalence of CVD risk factors such as hypertension and diabetes in Black
and Hispanic US populations, this finding is particularly of note.
Comorbid conditions
It was possible to investigate the association between co-morbidity and adherence on ten stud-
ies [34,35,37,39–42,45,47,49]. Given the increasing likelihood of comorbid conditions as peo-
ple age and the positive association between age and adherence the unadjusted analyses should
be interpreted cautiously.
The effect of increasing comorbidity on statin adherence: Strength of evidence = 0.
The number of co-morbid conditions as a measure of disease burden was counted in six stud-
ies [34,35,39,40,42,47]. One large high quality study reported the odds of being adherent
increased per additional comorbidity, after adjustment for age, gender, ethnicity and co-pay-
ment status [35]. One small high quality study reported that any co-morbidity increased the
odds of self-reported adherence by a factor of ten, but this was unadjusted for other factors
[47]. Three of these seven studies [34,39,42] calculated the Charlson Comorbidity index (CCI)
[50], a validated measure of disease burden. Unadjusted effects from Lavikainen et al. reveal
that participants with a CCI�1 were more likely to be adherent than those with no comorbid-
ity (OR 1.08 95%CI;1.00–1.16)) [39]. Similar sized unadjusted effects of having a score of one
or two on the CCI compared to zero were reported by Rublee et al. [42]; however adherence
was lower in the group with a CCI�3 compared to zero comorbidities (OR 0.75, 95%CI; 0.70–
0.80). In contrast, Aarnio et al. who used the same registry data as Lavikainen et al. found no
association between a one point increase in the CCI and the odds of being adherent in either
men or women after adjusting for the other covariates [34]. Perrault et al. used a different mea-
sure of comorbidity, the chronic disease score [51], and people classed as having a high chronic
disease score (�4) were more adherent (OR 1.43, 95%CI;1.14–1.20) [39].
Depression inversely associates with statin adherence—Strength of evidence = 3. The
existing evidence from five studies suggests that a diagnosis of depression does impact statin
adherence [31,34,40,42,49]. In one study (n = 116846, QA score = 16) depression (identified
from ICD-10 codes in Finnish registers) inversely associated with good adherence after adjust-
ment for other covariates including age and socioeconomic factors in men (OR 0.85, 95%CI;
0.79–0.93) and in women (OR 0.91, 95%CI; 0.85–0.95) [34]. One low quality study (n = 158,
QA score = 10) found an inverse association between depression and statin adherence using
the Hamilton Depression Rating Scale (HDRS), where higher scores indicate increasingly
depressive symptomatology [52], and adherence was measured using a Medication Event
Monitoring System (MEMS) [49]. Unadjusted analyses from one large low quality study that
identified depression from ICD-9 classification codes found no association between depres-
sion and adherence, nor did one small low quality study that used the Depression Anxiety and
Stress Scale to measure depression [31,42]. Finally, data from one low quality study included
use of antidepressants and this associated positively with adherence (OR 1.21, 95%CI; 1.17–
1.24).
Association of anxiety with statin adherence—strength of evidence = 0. Four studies
captured anxiety data and unadjusted effects were calculated [31,39,40,49]. Two studies found
(n = 42046, n high quality = 0) that anxiety did not associate with adherence [30,38]. Two stud-
ies found anxiety did associate with adherence (n = 243072, n high quality = 0) [40,49]. Cur-
rently, the extent to which anxiety associates with adherence is poorly understood and
evidenced.
The association of other mental health diagnoses and statin adherence—strength of evi-
dence = 3. Aarnio et al found the presence of a “mental disorder” increased the odds of being
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adherent to statins by approximately 40% in men and women after adjustment for other
comorbid conditions, socioeconomic, demographic and clinical factors [34]. Mental disorder
here refers to the ICD10 codes for schizophrenia, psychotic, bipolar and manic disorders;
there is evidence that cardiovascular mortality is higher in these groups and people may be
informed of their increased risk and therefore adhere accordingly.
Obesity inversely associated with statin adherence—Strength of evidence = 3. Aarnio
et al. found that obesity was associated with a lower odds of being adherent in women by
about 25%, the same size of effect was observed in men but the confidence intervals crossed
one (OR 0.81, 95%CI; 0.64–1.02) [33]. Rublee et al reported a very similar size of negative effect
(OR 0.83, 95%CI; 0.78–0.88) [42]. Three studies collected data on BMI; Halava et al (n = 6458,
QA score = 16) found, after adjustment for other clinical (depression, cancer and self-rated
health), demographic and lifestyle factors, people classified as being obese (BMI>29.9) or
overweight (25<BM<29.9 kg/m2) were approximately 15% less likely to be adherent than
people with a BMI�25 kg/m2 [46]. Importantly, Halava et al. considered cardiovascular
comorbidities and risks for CVD including diabetes and hypertension to moderate the rela-
tionship between lifestyle and adherence and these people were excluded from this particular
analysis. In contrast, two studies (n = 327, n high quality = 0) found that BMI did not differ
across adherent and non-adherent groups [31,45].
Other co-morbid conditions: Strength of evidence = 3. Aarnio et al. and Rublee et al.
included data on other comorbid conditions, these were identified from ICD10 and ICD9
codes collected in their respective Finnish and US registers (n = 195856, n high quality = 1)
[34,42]. Aarnio et al. (QA score = 16) calculated adjusted odds ratios for men and women sep-
arately [33], whereas data provided in the Rublee study (QA score = 13) were used to calculate
univariate odds ratios without stratification by gender [41].
Data were collected on cancer, respiratory disease, renal disease and rheumatoid arthritis.
A diagnosis of cancer associated with good statin adherence in the US cohort. (OR 1.34, 95%
CI; 1.26–1.43), Aarnio et al reported a smaller positive effect of cancer with stain adherence in
women (OR 1.11, 95%CI; 1.00–1.23) but not men (OR 1.02, 95%CI; 0.90–1.16) [33]. A diagno-
sis of asthma/chronic obstructive pulmonary disease (COPD) reduced the odds of adherence
for both men and women (OR 0.85, 95%CI; 0.79–0.91) in Aarnio et al., whereas in the US reg-
istry study Rublee et al. found a diagnosis of COPD increased the likelihood of adherence to
statins (OR 1.21, 95%CI; 1.12–1.31). Neither Aarnio et al. nor Rublee et al. reported an associa-
tion between renal insufficiency and adherence in (OR 1.27, 95%CI; 0.89–1.79) or women (OR
1.41, 95%CI; 0.96–2.04). Rublee et al. also found no association between chronic kidney dis-
ease and adherence (OR 1.14, 95%CI; 0.97–1.35). Finally, Aarnio et al. (n = 116846, QA
score = 16) found that women (OR 0.90, 95%CI; 0.82–0.99) but not men (OR 0.94, 95%CI;
0.83–1.08) with rheumatoid arthritis were less likely to adhere.
Health Behaviours & Lifestyle Factors
Eight studies evaluated health behaviours or lifestyle factors [30,33,35,41,44–47].
Alcohol misuse inversely associated with statin adherence—Strength of evidence = 4.
Four studies evaluated this association. Two studies (n = 151140, n high quality = 2) reported
that severe alcohol misuse, or alcoholism nearly doubled the risk of non-adherence after
adjustment for other factors, in particular Bryson et al. were able to control for potential con-
founding from level of education and smoking status [34,36]. Two studies (n = 6616, n high
quality = 1) found no effect of alcohol use or extreme drinking on statin adherence [45,46].
However the level of drinking captured in these studies may not be comparable to a diagnosis
of alcoholism or self-reported severe alcohol misuse.
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Physical activity does not associate with adherence—strength of evidence = 3. Halava
et al. (QA = 16, n = 6458) found no relationship between the level of self-reported activity mea-
sured using the metabolic equivalent of task (MET) index and adherence to statins either
unadjusted or adjusted analyses [46]. Accurately capturing physical activity via self-report is
challenging and further research using objective methods would better determine if there is a
link between adhering to statins and exercise.
The relationship between dietary behaviours and statin adherence—Strength of evi-
dence = 0. Two studies Guthrie (QA score = 5, n = 4548) and Mann et al (2007) (QA
score = 14, n = 71) reported contradictory findings on participants’ dietary behaviours and
adherence [47,48].
Health seeking behaviours associated with adherence—Strength of evidence = 3. Three
studies [42,47,48] contained information on other types of health seeking behaviours. In two
studies seeing a general practitioner increased the odds of being adherent by 20 to 25%
[42,48]. Mann et al. reported that visiting a healthcare practitioner for a cholesterol check
increased the odds of being adherent by a factor of four [46]. Rublee et al. (N = 79010, QA
score = 13) captured data on the number of people who attended clinic for preventive services
[41]. These included vaccinations, screening tests for bowel cancer, screening for osteoporosis,
cervical and breast cancer in women and prostate screening in men. The size of the association
varied depending upon the preventive service used but unadjusted analyses revealed people
who undertook these health seeking behaviours were 10 to 30% more likely to be adherent
during the one year adherence assessment period.
Other health behaviours associate with statins adherence—Strength of evidence = 1–
2. Guthrie et al investigated the association between other self-reported health behaviours
and adherence to statins (N = 4548, QA score = 5) [48]. Self-reported use of blood pressure
control treatments, trying to quit smoking and increased physical activity increase the odds of
being adherent by 40 to 50%. These were all unadjusted analyses and the study was deemed
low quality, therefore extrapolation of these results to the primary prevention population in
general is limited.
Health beliefs associate with adherence—Strength of evidence = 2. Mann et al. (N = 71,
QA score = 14) investigated the association between health beliefs and adherence using a
bespoke health belief questionnaire. Within the study there were conflicting findings
(Table 3). Participants who endorsed the beliefs “plan to use statin: < 6 months”, “personal
risk of a heart attack: less than average”, and “statins may be harmful to me” were two to three
times less likely to adhere than veterans who did not endorse these views [47].
Treatment-related predictors
Polypharmacy is not associated with statin adherence—Strength of evidence = 3.
Four studies investigated the association between the total number of medications a person
received and adherence to statins [32,34,39,45]. Aarnio et al (QA score = 16, N = 116846)
found that after adjustment for all other variables there was no increased likelihood of adher-
ence per additional medicine for men and women [34]. Lavikainen et al. (QA score = 13,
N = 42807) used a subsample from the same female cohort as Aarnio et al. but categorised
the total number of medications into groups of 1–2, 3–5 and 6–31 medications. In unad-
justed analyses patients who took more medications were 10 to 20% more likely to be adher-
ent [39]. Farsaei et al reported adherent patients took 1.4 more medications than non-
adherent patients (QA score = 7, n = 158) [45], and Braamskamp et al. found no association
after adjusting for other factors between using other medications (yes v no) and adherence
in their young familial hypercholesterolemia cohort (QA score = 13, N = 169) [32]. It is likely
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people on statins are prescribed other preventive CVD treatments such as antihypertensive
therapies.
Type of statin associates with adherence—Strength of evidence = 3. Four studies exam-
ined the type of statin and the direction and size of effect for particular statins varied greatly
across studies [31,34,37,40]. Given the high likelihood of bias from indication for particular
statins only Aarnio et al. is reported here because these analyses adjusted for potential con-
founders (Table 3). Compared to simvastatin, people were more likely to adhere to fluvastatin
and rosuvastatin, and less likely to adhere to lovastatin. After adjustment for other factors,
Finnish people using pravastatin were no more adherent than people who used simvastatin
[34].
Intensity of statin dose inversely associated with adherence = strength of evidence = 3.
Aarnio et al. set cut-offs of intensity for each type of statin and then classed people as having a
low, moderate or high dose of statins. Men on a moderate daily dose (OR 0.89, 95%CI;0.84–
0.94) and men on a high daily dose were less likely to adhere compared to men on a low daily
dose of statins (OR 0.70, 95%CI; 0.54–0.92) [34]. Similar and larger effects were observed in
the cohort of women, women on a high daily dose of statins were 60% less likely to adhere
compared to women on a low daily dose.
Timing of statin initiation associates with adherence = strength of evidence = 2. Lavi-
kainnen et al (QA score = 13, N = 42805) collected the year that the statin was initiated and,
compared to the year 2001, the proportions of women who were classed adherent were higher
for the years 2002, 2003 and 2004 [39]. In a cohort of patients (QA score = 13, N = 169) with
familial hypercholesterolemia, those who initiated statins before puberty were no more likely
to be currently adherent than those who were first prescribed statins post puberty [32].
Longer pharmacy prescription associates with statin adherence = strength of evi-
dence = 3. Batal et al. (QA score = 15, N = 3386) demonstrated that a longer supply of statins,
60 versus 30 days, was associated with an increased likelihood of being adherent after adjust-
ment for clinical and demographic factors (RR 1.40, 95%CI;1.27–1.55) [35].
Other treatment related factors = strength of evidence = 1–2. Al-Foraih reported an
unadjusted positive effect of longer statin duration on adherence; however, the authors did not
describe over what period of time this was measured, and this study may be susceptible to left
censorship [31]. Finally one large high quality study captured data on which professional had
prescribed the statin [43]. People were nearly four times more likely to be adherent if the initial
prescriber was a cardiologist than if the prescriber was a general practitioner, but this was an
unadjusted analysis, without adjusting for the number of CVD risk factors. This effect is likely
to be confounded by factors that influence whether the patient has a consultation with a cardi-
ologist rather than a general practitioner. Braamskamp et al. also reported that self-reported
side effects did not associate with adherence but noted that a minority of the cohort reported
side effects.
Medication costs association with adherence—Strength of evidence = 0. Two studies
using three different measures evaluated the impact of medication cost [34,35]. Aarnio et al.
2016 calculated the total out of pocket prescription costs for all medications and secondly by
calculating the specific co-payment patients made with respect to their first statin prescription
[34]. For every 50 euro increase in total costs there was approximately 10% increase in the like-
lihood of adhering. However, men and women who paid the highest tariff were over two times
more likely to non-adhere than those paying the lowest tariff. The analyses adjusted for other
socioeconomic factors such as income and education that may have confounded the associa-
tion between cost and adherence. One other study investigated co-payments and found mak-
ing co-payments (yes v no) did not affect adherence after adjustment for other factors [35],
however given that 80% of this cohort made some kind of co-payment a comparison akin to
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Aarnio which compared different levels of co-payment may have demonstrated a difference.
Given the heterogeneity of how cost was considered in the studies drawing a firm conclusion
on the impact of cost is difficult.
No association between type of healthcare organisation and statin adherence—Strength
of evidence = 3. Three studies investigated the type of healthcare delivery system and adher-
ence [35,42,43]. Slejko et al and Batal et al. extracted data from US drug registries and investi-
gated if the type of health plan associated with being adherent (Total N = 793396, N high
quality = 1). Batal et al. compared those with or without insurance cover and found those with
insurance cover were no more likely to be adherent than those without, after adjustment for
other factors [35]. Data from Slejko et al. in unadjusted analyses indicate that members of
commercial health insurance plans were no more likely to be adherent than those covered by
Medicaid or Medicare insurance plans [43]. One study (N = 11126, QA score = 13) did report
different rates of adherence for different healthcare organisations, based on the type of cover
[42]. Compared to people with point of service (POS) plans, which allow people to access any
healthcare professional at the point of service without paying into a plan, people with indem-
nity cover which does require regular payments but pays out when sickness occurs were twice
as likely to be adherent. People with POS plans that limited who they could see in the health-
care service were twice as likely to be non-adherent. However these were unadjusted analyses
that did not account for the different characteristics of people who use comprehensive indem-
nity insurance and those using basic insurance provided by the state, such as income and edu-
cation level.
Reasons for statin non-adherence
Farsaei et al. surveyed reasons for non-adherence in a diabetes sample [45]. The authors
reported 50% of 158 patients forgot to take their medications, the other reasons given were:
side effects (15%), because they did not take medications outside of the home (15%), because
they had run out (10%) and because they had achieved their therapeutic goal (10%). Guthrie
et al. reported reasons for discontinuation of pravastatin in their sample which included
patient decision (2%), side effects (5%), cost (4%), physician decision (3%), switched to other
medication (4%) other (6%) [48]. Harrison et al. (N = 98 QA score = 4) conducted telephone
interviews with people 12 weeks after their first statin prescription and found that only 26%
had filled their primary prescription [33]. Reasons for primary non-adherence included; gen-
eral concerns about medication (63%), decided to modify lifestyle instead (63%), fear of side
effects (53%), statin unnecessary (39%), low perceived illness severity (35%), fear of drug inter-
actions (16%), concerns about overuse of medications (16%), financial hardship (12%), did
not understand why provider prescribed medication (11%), did not understand purpose of
medication (8%), did not think statins were effective for condition (7%), inconvenient dosing
regimen (4%), and change in health plan (3%).
Discussion
This is the first systematic review specifically focused on predictors of adherence to statins in
the primary prevention setting. In total nineteen studies were included, and many more
could have been included if results had been stratified by primary and secondary prevention.
This was not a review of adherence rates overall, but the level of adherence in these reviewed
studies was sub-optimal, and further emphasises the importance of focusing on improving
adherence in the primary prevention population. There was moderate to strong evidence that
individuals with traditional CV risk factors have better adherence. In particular older age,
male gender, a diagnosis of diabetes, and a diagnosis of hypertension predicted better
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adherence. In contrast, the evidence that adherent patients adopt other healthy behaviours to
protect their heart was limited; only the evidence for an inverse relationship between alcohol
misuse and obesity (in women) and adherence was convincing. These findings challenge the
concept of the “healthy adherer effect”, since those who are more ill appear to adhere to stat-
ins better. These findings are predicted by the need-concern framework of health beliefs
which postulates those who perceive the greatest need despite medication concerns are more
likely to adhere [53].
There was moderate to strong evidence that socioeconomic predictors such as wealth,
employment status and level of education associate with statin adherence, and these effects
have been observed in systematic reviews that have included primary and secondary preven-
tion cohorts combined [20,21]. The association between higher socioeconomic status and
adherence may be related to fewer practical barriers to adhering. However in this review fac-
tors such as longer prescriptions fills, medication costs and type of healthcare provision, in
contrast to previous reviews that included secondary prevention populations, were inconsis-
tently associated with statin adherence. The type and intensity of statin dose independently
associated with statin adherence [34]. Whether these associations are underpinned by medica-
tion concern, such as those reported by Mann et al. or increased levels of adverse events is
unknown. Only one study examined the relationship between side effects and non-adherence
and returned a null finding [32]. However side effects were given as a reason for both non-
commencement [33] and non-adherence [45] in two small studies, therefore this merits fur-
ther investigation.
These findings align with results from previous reviews that increased health risks and male
gender associate with better adherence [20,21]. In this review most studies reported a positive
linear relationship between age and adherence. However, previous reviews indicate that age is
nonlinearly related to adherence, suggesting age is an important modifier of the relationship
between perceived risk of CVD and adherence.
In this review the association between higher income and better adherence was much
clearer for men than women, and higher levels of education associated with lower statin adher-
ence in women and higher statin adherence in men. The apparent sex dependent effect of
socioeconomic status upon adherence was discussed by Aarnio et al. and they cite the unmea-
sured association between unhealthy lifestyles and low health literacy as an explanation [34].
There was strong evidence from this review that excess alcohol consumption in men and
women was associated with lower adherence to statins, and strong evidence for women but
not men with obesity to be less adherent. These associations may be partly underpinned by
low health literacy. Educated men and women are likely to be more health literate. Men and
women may perceive their susceptibility to primary CVD differently because sex informs the
calculation of CVD risk. Alternatively, men and women may balance the overall need for a
preventive medication with medication concerns differently.
These data suggest that individuals who are younger, female, or do not have diabetes or
hypertension may have a lower perceived risk of developing CVD or experiencing a CVE [54],
and reminders alone may not be sufficient to change behaviour [55]. The very limited evidence
from this review supports the hypothesis that low perceived susceptibility to CVD indepen-
dently predicted poor adherence [47]. Interventions that aim to improve patient and/or physi-
cian understanding of personal risk of incident CVD have demonstrated improved statin
adherence in the short-term [56,57]. Lower risk individuals may also have less contact with
medical professionals and there was limited evidence that attending clinic, or having a choles-
terol check associated with better statin adherence.
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Methodological limitations
The findings of this review must be interpreted in the context of its limitations. What consti-
tutes a primary prevention population was fairly consistent across studies. One study excluded
patients with diabetes and hypertension as Halava et al. considered these CVD risks may mod-
ify the relationship between lifestyle factors and adherence [46]. Data pertaining to potential
predictors were extracted from ten studies to calculate univariable associations between these
factors and statin adherence. The interrelatedness of clinical, socioeconomic and lifestyle fac-
tors cannot be addressed in such analyses. Where studies conducted multivariable analyses
with large numbers of variables collinearity may not have been sufficiently addressed. Further
research is therefore required to understand the relationship between the presence of cardio-
vascular risks, adoption of healthy lifestyles and statin adherence.
A limitation of measuring adherence is the risk of measurement reactivity; this was recently
demonstrated in two RCTs designed to improve adherence. Patients were screened for sub
optimal adherence based on their pharmacy refill records before entry in to the trial. These tri-
als objectively measured adherence using a MEMS. After 3 months the level of adherence was
very high irrespective of treatment arm with no significant differences. Given that only 1% of
the sampling frame agreed to participate in these trials and the median patient adherence
before entry into these trials was ~60% it appears that the effective intervention to optimise
adherence involved the patient’s decision to participate in these studies, and potentially the
patient’s response to the electronic monitoring of their medication [58]. However, most of the
studies included in this review used objective indirect methods to assess adherence, meaning
the participant was unaware that they were being monitored. Therefore, there is limited bias in
these data from measurement reactivity. Prescription refill data still have limitations both
because there is an underlying assumption that all prescribed pills were taken between fills and
because it is not possible to identify periods of time when a prescription is not filled because of
medical advice to temporarily stop a statin.
Fixed dose combination (FDC) therapy or “polypill” therapies that combine blood pressure,
cholesterol lowering and antiplatelet treatments into a single pill, are hypothesised as one strat-
egy to improve adherence. The authors did not include FDC trials in this review because
adherence to a polypill necessarily cannot be specific to a statin. Adherence to FDC compared
to multiple CVD medications was investigated as part of a Cochrane review and levels of
adherence were higher in the FDC arm but this was investigated in just one study [59]. In our
review, four studies investigated polypharmacy and there was no evidence that polypharmacy
lowered adherence to statins; one study reported that adherence increased per additional med-
ication. Similar inconsistent effects have been observed in previous reviews. Given the current
evidence base, FDC therapy is unlikely to increase adherence to statins. Other features of med-
icine use (time taken to complete, regimen complexity) may have a greater impact on long-
term adherence than simply the number of medications.
Future research
This review draws attention to the limited number of well-designed observational studies
examining multivariable predictors of adherence. Synthesis of the existing data allows one to
infer possible mechanisms but there are a number of areas where more research is required.
Firstly, is high perceived risk of primary CVD the mechanism that explains the observed asso-
ciations between traditional CVD risk factors and statin adherence? Secondly, given there is
evidence of sex dependent effects of socioeconomic factors on adherence, what are the drivers
of these sex differences? Potentially, there is an interaction between gender and level of health
literacy which results in gendered beliefs about the need for and concerns about statins, but
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this still needs demonstrating empirically. Thirdly, given that side effects and fear of side
effects were given as reasons for discontinuation, it is remarkable that only one study investi-
gated the relationship between side effects and adherence [32]. Patient tolerance of side effects
could explain the observed links between dosing and type of statin and adherence [34], alterna-
tively, people with prior negative expectations may misattribute symptoms such as muscular
pain (myalgia) to statins use [60]. The low level of reporting of adverse events prevents the
authors from drawing any conclusion about the effect of side effects on statin adherence.
Therefore, future research should address the relationship between prior concerns about side
effects, reported side effects and statins adherence. Fourthly, the relationship between lifestyle
factors and statins adherence is poorly understood, nevertheless there is some evidence these
associations may also be modified by patient factors. Future analyses using high quality pro-
spective data could investigate if gender and age modify the association between lifestyle fac-
tors and adherence. Such analyses would allow one to infer the possible drivers of these
differences. For example, high physical activity in a middle aged woman may predict poor
statin adherence, because this woman perceives herself to be at low risk of disease, whereas
high physical activity in an older man may predict high adherence because both his behaviours
are underpinned by a high perceived risk of personal morbidity/mortality. Similarly, data from
studies that investigate if the presence or absence of diabetes and/or hypertension alters the
relationship between lifestyle factors and statins adherence could be used to infer the latent
effects of health beliefs.
Conclusion
There is an ongoing debate about how widespread the use of statins should be in the field of
primary prevention. Hence, improving adherence should not be at the expense of supporting
people to make healthy lifestyle changes. This review makes clear the predictors of adherence
common to primary and secondary prevention settings. There also appear to be important sex
and age dependent differences that are specific to adherence to statins prescribed for the pri-
mary prevention of CVD. Further research is needed to understand better the underlying
mechanisms of statin adherence.
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